CD19 and diffuse large B-cell lymphoma: Additionally, a phase I study assessed durvalumab with the CD19-targeted antibody–drug conjugate loncastuximab tesirine in relapsed/refractory B-cell lymphomas, including DLBCL, showing preliminary anti-tumor activity with manageable toxicity [67].